Vyriad Secures $85M Series B Funding

Vyriad has secured $85,000,000 in funding from investors to advance its development of targeted genetic therapies.

This capital infusion is intended to accelerate the company's research and clinical development efforts, underscoring investor confidence in Vyriad's innovative approach to treating various cancers.

The funding round is poised to support the company's ongoing initiatives in the field of oncolytic virotherapy and gene editing applications.

At its core, Vyriad engineers viruses, viral vectors, and viral envelope glycoproteins to deliver genes directly to targeted cells.

This core technology facilitates oncolytic virotherapy, in vivo gene therapies, and gene editing applications.

The company is actively testing its oncolytic viruses as monotherapies and in combination with immuno-oncology drugs across a range of clinical studies.

Phase 1-2 clinical trials are currently active for several cancer types, including non-small cell lung cancer, squamous cell carcinoma of the head and neck, metastatic colorectal cancer, breast cancer, and bladder cancer, among others.

Vyriad also holds clinical research collaboration agreements with leading institutions such as Regeneron and Mayo Clinic.

The $85,000,000 raised will be strategically deployed to advance Vyriad's pipeline of genetic therapies, support its ongoing clinical studies, and expand its research and development initiatives.

This investment is critical for the continued progression of its therapeutic candidates through clinical stages.

The company plans to use the funds to further its mission of creating the next generation of targeted treatments, aiming to bring new options to patients battling complex diseases.

This funding is expected to support Vyriad's continued growth and its efforts to expand its therapeutic reach in oncology.